Abstract: Dosage regimens of anti-Blood Dendritic Cell Antigen 2 antibodies are provided for use in the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus.

Abstract: Provided herein are biphasic dosing protocols for natalizumab therapy comprising both standard and extended interval dosing and subcutaneous administration.

Abstract: The present disclosure provides methods of treatment using (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide and pharmaceutically salts thereof.

Abstract: The present invention is directed to a novel method of treating a disease or condition mediated by modulation of Nav1.

Abstract: Methods and pharmaceutical compositions for reducing number of gout flares experienced by a patient are disclosed. The methods can comprise administering to a patient with hyperuricemia an effective amount of a xanthine oxidase inhibitor in a modified release dosage form once daily or in an immediate release dosage form two or more times daily to prevent at least one gout flare or reduce the number of gout flares experienced by the patient.

Abstract: In solid-state memory, such as flash memory, a section of memory is typically erased prior to each time data is programmed therein. In contrast, systems and methods for programming a solid-state memory device with writes from different data sets without an intervening erase are disclosed. For example, the memory device may first erase a block and thereafter program the block with a first data set, with some cells in an erased state and other cells in a non-erased state. After programming the first data set into the block and without erasing the block, the memory device programs the block with a second data set that is at least partially different from the first data set. In this regard, some of the cells, which were in a non-erased state after programming with the first data set, are in an erased state after programming with the second data set.

Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.

Abstract: Methods and pharmaceutical compositions for reducing number of gout flares experienced by a patient are disclosed. The methods can comprise administering to a patient with hyperuricemia an effective amount of a xanthine oxidase inhibitor in a modified release dosage form once daily or in an immediate release dosage form two or more times daily to prevent at least one gout flare or reduce the number of gout flares experienced by the patient.

Abstract: Co-administration of febuxostat and theophylline to a hyperuricemic patient suffering from gout is disclosed.

Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.

Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.

Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.